Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02456610
Other study ID # 307-CMV/EBV-CTL
Secondary ID
Status Recruiting
Phase Phase 1
First received May 21, 2015
Last updated February 18, 2016
Start date May 2015
Est. completion date August 2016

Study information

Verified date February 2016
Source Affiliated Hospital to Academy of Military Medical Sciences
Contact Zhang Bin, M.D., Ph.D.
Phone +86-010-6694-7125
Email zb307ctc@163.com
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) cause significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients in China. Antiviral drugs given either prophylactically or as early therapy for patients with detectable viral loads appear to be an effective strategy for reducing viral infections. However, long-term treatment with these drugs is associated with significant toxicity, expense and the appearance of drug resistant virus isolates ultimately resulting in treatment failure. CMV and EBV specific T cells infusion to immunocompromised patients following HSCT is able to induce a successful anti-viral response. The primary purpose of this study is to determine the safety and efficacy of the infusion of CMV and EBV specific cytotoxic T cells (CTLs) for patients with CMV and EBV reactivation or infection.


Description:

To generate CMV/EBV specific CTLs, G-CSF mobilized hemopoietic progenitor cell (G-HPC) products or nonmobilized peripheral blood apheresis collectings were stimulated with CMV/EBV specific peptides covering most HLA alleles among Chinese populations. Once the investigators made sufficient numbers of T cells, they tested their ex vivo properties.Then a fraction of CTLs were separated for immediate infusion and the others were frozen for further infusion.

If the donor was available, the donor derived CTLs were started to produce when CMV reactivation was detected by qPCR in recipients peripheral blood. Otherwise, autologous CTLs were used. For patients at high risk of developing CMV/EBV infections after stem cell transplantation, a small part of G-HPC products was extracted for CTLs generation.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date August 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with any type of allogeneic HSCT

- CMV, adenovirus or EBV activation or infection which is defined as below. EBV/CMV reactivation is defined as CMV/EBV DNA levels > 1000 IU/ml for a single test or > 500 IU/ml for two consecutive tests. EBV/CMV related disease were defined as the demonstration of CMV/EBV biopsy specimen or clinical diagnosis through symptoms, signs or radiography.

- Written informed consent and/or signed assent line from patient, parent or guardian

- Positive CMV or EBV serology of the donor

- Absence of severe renal disease (Creatinine > 3x upper limit normal)

- Absence of severe hepatic disease (Bilirubin > 3x upper limit normal, AST > 3x upper limit normal)

- Life expectancy > 30 days

Exclusion Criteria:

- Active acute GVHD grades II-IV

- Received donor lymphocytes infusion(DLI) within 30 days

- Received ATG or other immunosuppressive monoclonal antibodies within 30 days

- Uncontrolled acute infections

- Active and relapse of malignancy

- Received steroids treatment more than 0.5 mg/kg/day prednisone

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Biological:
CMV/EBV specific CTLs
Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.

Locations

Country Name City State
China Affiliated Hospital to Academy of Military Medical Sciences Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Affiliated Hospital to Academy of Military Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity of adoptive transfer of CMV/EBV specific CTLs(The increase of temperature by 1? and/or the appearance of rash within 24h after infusion) Assessment of acute transfusion toxicity within 24 hours after adoptive CTLs transfer 24 hours Yes
Primary Assessment of viral load response to the CTL infusion assessed by CMV/EBV specific PCR of peripheral blood Assess the effect of the CTL infusion on viral load 3 months No
Secondary The incidence of ?~?°aGVHD within 30 days after the last dose of CTL infusion 3 months Yes
Secondary Reconstitution of antiviral immunity monitored by flow cytometry 6 months No
Secondary Number of patients with chronic GVHD 6 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05568953 - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Phase 2
Not yet recruiting NCT05953233 - School Inner City Air Study N/A
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Completed NCT01570283 - ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus Phase 1/Phase 2
Not yet recruiting NCT01159470 - The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children N/A
Recruiting NCT02532452 - Third Party Viral Specific T-cells (VSTs) Phase 2
Recruiting NCT05246098 - REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI
Recruiting NCT05603650 - Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract N/A
Completed NCT04525456 - Immune Responses With Reduxium N/A
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Completed NCT04267809 - Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection Phase 2
Completed NCT00341081 - Validation of Self-Reported Needle Sharing Among Injection Drug Users N/A
Recruiting NCT04088916 - Proviral DNA as a Target for HIV-1 Resistance Analysis
Terminated NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Terminated NCT00952185 - Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers N/A
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Active, not recruiting NCT04254991 - A Controlled, Blinded Study to Validate the Diagnostic Accuracy and Assess the Clinical Utility of a Host-response Based Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients Presenting to the ED With Suspicion of Acute Infection
Completed NCT05897801 - Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO
Terminated NCT02696291 - Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects Phase 1